Effective August 4, 2026, 2,94,30,987 equity shares of face value Rs. 5 each have been listed and admitted to trading on the NSE
Telangana Life Sciences, BITS Pilani and RMIT Australia launch industry-integrated PhD programme for life sciences
GenomeIndia, Bio-AI Hubs, IBDC and ANRF-led initiatives strengthen India's AI-enabled biotechnology ecosystem with focus on healthcare, biomanufacturing and translational research
National programme aims to accelerate development of bio-butanol technologies for India's clean energy and industrial transition
The partnership gives the German pharmaceutical company access to one of the country's leading academic and biotech networks focused on nucleic acid therapeutics
With new distribution agreements in Argentina, Hong Kong & Singapore
Lilly will also gain VLS-01, a buccal film formulation of DMT currently in Phase 2b testing, along with AtaiBeckley's broader pipeline of next-generation neuroplastogens aimed at restoring the brain's ability to form new neural connections
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
New AMF Series combines industry-leading 1000:1 turndown capability, predictive diagnostics, and digital connectivity in a footprint no larger than a standard Post-it Note pad
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Subscribe To Our Newsletter & Stay Updated
